In the last six months Pfizer’s stock (NYSE: PFE) has underperformed Merck (NYSE: MRK) and J&J (NYSE: JNJ) primarily due to ...
New York-based Pfizer Inc. (PFE) is a leading global biopharmaceutical company. With a market cap of $139.3 billion, it is ...
If you are wondering whether Pfizer's current share price reflects its underlying value, you are not alone. This article will ...
Pfizer shares fall nearly 5% in a month after weak 2026 guidance, sparking debate over buying the dip or staying cautious.
SHANGHAI, CHINA - 2025/11/08: The Pfizer logo is presented at the 8th China International Import Expo. (Photo by Sheldon Cooper/SOPA Images/LightRocket via Getty Images) Pfizer (PFE) is encountering ...
The Daily Overview on MSN
How safe is Pfizer's dividend as 2026 begins?
Pfizer heads into 2026 with a share price still shaped by the boom and bust of COVID products and a shareholder base that increasingly cares more about income than growth. The company's dividend has ...
10d
Could Pfizer Inc.'s (NYSE:PFE) Weak Financials Mean That The Market Could Correct Its Share Price?
Pfizer's (NYSE:PFE) stock is up by 4.7% over the past three months. Given that the markets usually pay for the long-term ...
Pfizer PFE stock has declined around 3% this week. On Dec. 16, the company announced its financial guidance for 2026, which fell short of investor expectations. Pfizer expects total revenues for 2026 ...
Pfizer is a Buy at low valuation but faces a 2030 patent cliff, COVID sales declines, and LOE risks. Click here to read an analysis of PFE stock now.
Pfizer Inc. (NYSE: PFE) is scheduled to provide its full-year 2026 financial guidance on Tuesday, with Bank of America Securities expecting the company's growth profile to closely resemble conditions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results